Zhejiang Cheng Yi Pharmaceutical announced that the Amikacin sulfate injection produced by the company has passed the consistency evaluation for the quality and efficacy of generic drugs. This Pharmaceutical has more than 100 manufacturers approved for sale in China and is classified as Category A in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Pharmaceutical Catalog" 2023 edition. As of the date of this announcement, the company has invested approximately RMB 5.2559 million in the consistent evaluation of this Pharmaceutical. The passage of the consistency evaluation is beneficial for enhancing market competitiveness and has a positive impact on market sales.
诚意药业:硫酸阿米卡星注射液通过仿制药一致性评价
Zhejiang Cheng Yi Pharmaceutical: Amikacin sulfate injection has passed the consistency evaluation for generic drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.